EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

Chang-Yun Li, Wanhe Wang, Chung-Hang Leung, Guan-Jun Yang, Jiong Chen

Molecular Cancer · 2024

DOI: 10.1186/s12943-024-02011-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Cancer, 2024. Verfasst von Chang-Yun Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, Ningbo University, Ningbo, 315211, Zhejiang…. Hauptthemen laut MEDLINE: Breast Neoplasms, Histone Demethylases, Molecular Targeted Therapy. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone receptor (PR) positive, human epidermal growth factor receptor 2 (HER2) positive, and triple-negative BC (TNBC). Based on the stages and subtypes of BC, various treatment methods are available with variations in the rates of progression-free disease and overall survival of patients. However, the treatment of BC still faces challenges, particularly in terms of drug resistance and recurrence. The study of epigenetics has provided new ideas for treating BC. Targeting aberrant epigenetic factors with inhibitors represents a promising anticancer strategy. The KDM5 family includes four members, KDM5A, KDM5B, KDM5C, and KDMD, all of which are Jumonji C domain-containing histone H3K4me2/3 demethylases. KDM5 proteins have been extensively studied in BC, where they are involved in suppressing or promoting BC depending on their specific upstream and downstream pathways. Several KDM5 inhibitors have shown potent BC inhibitory activity in vitro and in vivo, but challenges still exist in developing KDM5 inhibitors. In this review, we introduce the subtypes of BC and their current therapeutic options, summarize KDM5 family context-specific functions in the pathobiology of BC, and discuss the outlook and pitfalls of KDM5 inhibitors in this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHistone DemethylasesMolecular Targeted TherapyHumansFemaleAnimalsAntineoplastic AgentsEpigenesis, GeneticGene Expression Regulation, NeoplasticJumonji Domain-Containing Histone DemethylasesBiomarkers, Tumor

Stichwörter der Autor:innen

Breast cancerHistone demethylationKDM5KDM5 inhibitorsTherapeutic target

Substanzen

Histone DemethylasesAntineoplastic AgentsJumonji Domain-Containing Histone DemethylasesBiomarkers, Tumor

Autor:innen und Institutionen

  • State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, Ningbo University, Ningbo, 315211, Zhejiang, China.
  • Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo University, Ningbo, 315211, China.
  • Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi, 710072, China.
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China. duncanleung@um.edu.mo.
  • Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Macau, China. duncanleung@um.edu.mo.
  • Macao Centre for Research and Development in Chinese Medicine, University of Macau, Macau, China. duncanleung@um.edu.mo.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Li, C. Y., Wang, W., Leung, C. H., Yang, G. J., & Chen, J. (2024). KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Molecular Cancer. https://doi.org/10.1186/s12943-024-02011-0

Vancouver

Li CY, Wang W, Leung CH, Yang GJ, Chen J. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Molecular Cancer. 2024. doi:10.1186/s12943-024-02011-0

BibTeX
@article{Li2024,
  author = {Li, Chang-Yun and Wang, Wanhe and Leung, Chung-Hang and Yang, Guan-Jun and Chen, Jiong},
  title = {KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges},
  journal = {Molecular Cancer},
  year = {2024},
  doi = {10.1186/s12943-024-02011-0}
}
Kostenlos starten →